Travis Steed
Stock Analyst at Barclays
(2.71)
# 1,961
Out of 4,896 analysts
86
Total ratings
43.48%
Success rate
6.28%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $175.97 | +48.32% | 9 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $237.94 | +34.49% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $132.02 | +13.62% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $73.80 | +15.18% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $78.05 | +15.31% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $16.18 | +97.78% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $28.70 | +56.79% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $19.39 | +132.08% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $389.46 | -19.12% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $289.32 | +1.96% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $11.89 | +34.57% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $15.59 | +111.67% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $93.79 | +70.59% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $512.06 | -38.48% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $2.90 | +175.86% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $10.47 | +138.78% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.71 | +477.84% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $83.37 | +49.93% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $89.92 | +61.25% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $103.20 | -50.58% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $51.27 | +241.33% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $12.59 | +328.91% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $81.31 | -72.94% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $175.97
Upside: +48.32%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $237.94
Upside: +34.49%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $132.02
Upside: +13.62%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $73.80
Upside: +15.18%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $78.05
Upside: +15.31%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $16.18
Upside: +97.78%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $28.70
Upside: +56.79%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $19.39
Upside: +132.08%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $389.46
Upside: -19.12%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $289.32
Upside: +1.96%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $11.89
Upside: +34.57%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $15.59
Upside: +111.67%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $93.79
Upside: +70.59%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $512.06
Upside: -38.48%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $2.90
Upside: +175.86%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $10.47
Upside: +138.78%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.71
Upside: +477.84%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $83.37
Upside: +49.93%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $89.92
Upside: +61.25%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $103.20
Upside: -50.58%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $51.27
Upside: +241.33%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $12.59
Upside: +328.91%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $81.31
Upside: -72.94%